Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Inventory (2020 - 2025)

Historic Change in Inventory for Eton Pharmaceuticals (ETON) over the last 6 years, with Q3 2025 value amounting to -$5.6 million.

  • Eton Pharmaceuticals' Change in Inventory fell 421846.15% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 52886.13%. This contributed to the annual value of $1.3 million for FY2024, which is 27005.65% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Change in Inventory stood at -$5.6 million, which was down 421846.15% from $11.4 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Change in Inventory registered a high of $11.4 million during Q2 2025, and its lowest value of -$5.6 million during Q3 2025.
  • Over the past 5 years, Eton Pharmaceuticals' median Change in Inventory value was $21000.0 (recorded in 2022), while the average stood at $428705.9.
  • Within the past 5 years, the most significant YoY rise in Eton Pharmaceuticals' Change in Inventory was 465080.0% (2025), while the steepest drop was 421846.15% (2025).
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Change in Inventory stood at $216000.0 in 2021, then tumbled by 64.81% to $76000.0 in 2022, then tumbled by 284.21% to -$140000.0 in 2023, then surged by 302.14% to $283000.0 in 2024, then crashed by 2083.75% to -$5.6 million in 2025.
  • Its last three reported values are -$5.6 million in Q3 2025, $11.4 million for Q2 2025, and -$468000.0 during Q1 2025.